bluebird bio Balance Sheet Health

Financial Health criteria checks 0/6

bluebird bio has a total shareholder equity of $-5.8M and total debt of $80.7M, which brings its debt-to-equity ratio to -1394.4%. Its total assets and total liabilities are $465.1M and $470.8M respectively.

Key information

-1,394.4%

Debt to equity ratio

US$80.68m

Debt

Interest coverage ration/a
CashUS$70.65m
Equity-US$5.79m
Total liabilitiesUS$470.84m
Total assetsUS$465.06m

Recent financial health updates

Is bluebird bio (NASDAQ:BLUE) In A Good Position To Invest In Growth?

Oct 13
Is bluebird bio (NASDAQ:BLUE) In A Good Position To Invest In Growth?

Here's Why We're A Bit Worried About bluebird bio's (NASDAQ:BLUE) Cash Burn Situation

Jul 13
Here's Why We're A Bit Worried About bluebird bio's (NASDAQ:BLUE) Cash Burn Situation

Recent updates

bluebird bio, Inc.'s (NASDAQ:BLUE) Revenues Are Not Doing Enough For Some Investors

Nov 15
bluebird bio, Inc.'s (NASDAQ:BLUE) Revenues Are Not Doing Enough For Some Investors

bluebird bio: Scientific Success And Financial Success, And The Gap Between

Sep 26

bluebird bio's Flight Through Financial Fog And Fierce Rivals

Jun 27

bluebird bio Is Priced Below IP Value

Mar 23

Bluebird Bio: Innovative Therapies, Monetary Setbacks

Jan 25

Is bluebird bio (NASDAQ:BLUE) In A Good Position To Invest In Growth?

Oct 13
Is bluebird bio (NASDAQ:BLUE) In A Good Position To Invest In Growth?

Here's Why We're A Bit Worried About bluebird bio's (NASDAQ:BLUE) Cash Burn Situation

Jul 13
Here's Why We're A Bit Worried About bluebird bio's (NASDAQ:BLUE) Cash Burn Situation

Bluebird, Real Endpoints team up to increase access to pricey gene therapy Zynteglo

Oct 04

Bluebird bio names interim finance chief

Sep 26

Bluebird bio jumps 17% on FDA approval of new gene therapy

Sep 19

bluebird bio' chief strategy and financial officer to depart

Sep 12

FDA approves bluebird bio's Zyntego beti-cel gene therapy for beta thalassemia

Aug 17

bluebird bio: Potential For 3 Gene Therapy Approvals In 12 Months Makes Buy Case

Jun 22

bluebird bio: Beaten Down Biotech With Possible Long-Term Potential

May 09

Financial Position Analysis

Short Term Liabilities: BLUE has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: BLUE has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: BLUE has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: BLUE's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: BLUE has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: BLUE has less than a year of cash runway if free cash flow continues to grow at historical rates of 12.9% each year.


Discover healthy companies